Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Other Operating Expenses (2017 - 2023)

BeOne Medicines (BEIGF) has disclosed Other Operating Expenses for 7 consecutive years, with $188000.0 as the latest value for Q2 2023.

  • Quarterly Other Operating Expenses fell 99.74% to $188000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $188000.0 through Mar 2024, up 100.29% year-over-year, with the annual reading at $71.5 million for FY2020, 1.4% down from the prior year.
  • Other Operating Expenses for Q2 2023 was $188000.0 at BeOne Medicines, up from $187000.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $76.7 million in Q3 2022, with the low at -$213.5 million in Q4 2022.
  • Average Other Operating Expenses over 5 years is $8.0 million, with a median of $19.4 million recorded in 2019.
  • The sharpest move saw Other Operating Expenses skyrocketed 229.08% in 2019, then plummeted 649.82% in 2021.
  • Over 5 years, Other Operating Expenses stood at $18.3 million in 2019, then rose by 16.11% to $21.3 million in 2020, then tumbled by 649.82% to -$116.9 million in 2021, then plummeted by 82.61% to -$213.5 million in 2022, then soared by 100.09% to $188000.0 in 2023.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $188000.0, $187000.0, and -$213.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.